Novavax, Inc. (NVAX)
USD 6.17
(-1.12%)
USD 6.17
(-1.12%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 779.12 Million USD | -16.54% |
| 2022 | 1.34 Billion USD | -52.66% |
| 2021 | 2.83 Billion USD | 217.47% |
| 2020 | 892.31 Million USD | 501.86% |
| 2019 | 148.25 Million USD | -28.79% |
| 2018 | 208.2 Million USD | 2.62% |
| 2017 | 202.88 Million USD | -28.68% |
| 2016 | 284.46 Million USD | 47.02% |
| 2015 | 193.48 Million USD | 94.73% |
| 2014 | 99.36 Million USD | 52.57% |
| 2013 | 65.12 Million USD | 75.79% |
| 2012 | 37.04 Million USD | 26.6% |
| 2011 | 29.26 Million USD | -24.65% |
| 2010 | 38.83 Million USD | 2.99% |
| 2009 | 37.7 Million USD | 6.45% |
| 2008 | 35.42 Million USD | 12.23% |
| 2007 | 31.56 Million USD | 38.33% |
| 2006 | 22.81 Million USD | 111.9% |
| 2005 | 10.76 Million USD | -63.17% |
| 2004 | 29.23 Million USD | 13.39% |
| 2003 | 25.78 Million USD | -21.88% |
| 2002 | 33 Million USD | 12.76% |
| 2001 | 29.26 Million USD | 85.12% |
| 2000 | 15.81 Million USD | 155.02% |
| 1999 | 6.2 Million USD | 0.0% |
| 1998 | 6.2 Million USD | 10.71% |
| 1997 | 5.6 Million USD | -5.08% |
| 1996 | 5.9 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 217.32 Million USD | 13.31% |
| 2024 Q1 | 183.77 Million USD | -43.63% |
| 2023 FY | 1.11 Billion USD | -16.54% |
| 2023 Q3 | 48.76 Million USD | -84.43% |
| 2023 Q2 | 313.19 Million USD | 15.04% |
| 2023 Q1 | 272.25 Million USD | -22.2% |
| 2023 Q4 | 326.03 Million USD | 568.55% |
| 2022 Q3 | 427.17 Million USD | 7.38% |
| 2022 Q4 | 349.94 Million USD | -18.08% |
| 2022 Q1 | 479.47 Million USD | -54.21% |
| 2022 FY | 1.34 Billion USD | -52.66% |
| 2022 Q2 | 397.8 Million USD | -17.03% |
| 2021 FY | 2.83 Billion USD | 217.47% |
| 2021 Q2 | 643.84 Million USD | -1.83% |
| 2021 Q1 | 655.86 Million USD | 41.8% |
| 2021 Q3 | 485.98 Million USD | -24.52% |
| 2021 Q4 | 1.04 Billion USD | 115.47% |
| 2020 Q3 | 350.96 Million USD | 567.68% |
| 2020 Q2 | 52.56 Million USD | 100.06% |
| 2020 FY | 892.31 Million USD | 501.86% |
| 2020 Q1 | 26.27 Million USD | -29.98% |
| 2020 Q4 | 462.51 Million USD | 31.78% |
| 2019 Q4 | 37.52 Million USD | 41.54% |
| 2019 FY | 148.25 Million USD | -28.79% |
| 2019 Q3 | 26.51 Million USD | -33.76% |
| 2019 Q1 | 44.2 Million USD | -16.02% |
| 2019 Q2 | 40.02 Million USD | -9.46% |
| 2018 Q1 | 53.16 Million USD | -8.64% |
| 2018 FY | 208.2 Million USD | 2.62% |
| 2018 Q3 | 49.63 Million USD | -5.93% |
| 2018 Q2 | 52.76 Million USD | -0.75% |
| 2018 Q4 | 52.63 Million USD | 6.05% |
| 2017 FY | 202.88 Million USD | -28.68% |
| 2017 Q2 | 48.2 Million USD | 3.65% |
| 2017 Q3 | 49.98 Million USD | 3.69% |
| 2017 Q4 | 58.19 Million USD | 16.44% |
| 2017 Q1 | 46.5 Million USD | -21.77% |
| 2016 Q3 | 66.53 Million USD | -15.78% |
| 2016 FY | 284.46 Million USD | 47.02% |
| 2016 Q2 | 79 Million USD | -0.6% |
| 2016 Q4 | 59.44 Million USD | -10.66% |
| 2016 Q1 | 79.48 Million USD | -6.22% |
| 2015 Q3 | 36.97 Million USD | 15.09% |
| 2015 Q4 | 84.75 Million USD | 129.21% |
| 2015 Q2 | 32.13 Million USD | 1.26% |
| 2015 Q1 | 31.73 Million USD | -10.75% |
| 2015 FY | 193.48 Million USD | 94.73% |
| 2014 Q3 | 23.97 Million USD | 14.13% |
| 2014 FY | 99.36 Million USD | 52.57% |
| 2014 Q2 | 21 Million USD | 11.59% |
| 2014 Q1 | 18.82 Million USD | -7.71% |
| 2014 Q4 | 35.55 Million USD | 48.28% |
| 2013 Q2 | 14.79 Million USD | 22.03% |
| 2013 Q1 | 12.12 Million USD | 0.14% |
| 2013 FY | 65.12 Million USD | 75.79% |
| 2013 Q4 | 20.39 Million USD | 14.56% |
| 2013 Q3 | 17.8 Million USD | 20.33% |
| 2012 FY | 37.04 Million USD | 26.6% |
| 2012 Q2 | 7.84 Million USD | -5.8% |
| 2012 Q3 | 8.77 Million USD | 11.94% |
| 2012 Q4 | 12.1 Million USD | 37.98% |
| 2012 Q1 | 8.32 Million USD | 168.4% |
| 2011 Q4 | 3.1 Million USD | -65.45% |
| 2011 FY | 29.26 Million USD | -24.65% |
| 2011 Q1 | 8.26 Million USD | 16.67% |
| 2011 Q2 | 8.92 Million USD | 7.96% |
| 2011 Q3 | 8.97 Million USD | 0.61% |
| 2010 FY | 38.83 Million USD | 2.99% |
| 2010 Q2 | 9.47 Million USD | -18.06% |
| 2010 Q1 | 11.56 Million USD | -18.72% |
| 2010 Q4 | 7.08 Million USD | -33.89% |
| 2010 Q3 | 10.71 Million USD | 13.08% |
| 2009 Q3 | 8.46 Million USD | 7.69% |
| 2009 FY | 37.7 Million USD | 6.45% |
| 2009 Q2 | 7.85 Million USD | 9.79% |
| 2009 Q4 | 14.22 Million USD | 68.12% |
| 2009 Q1 | 7.15 Million USD | -22.87% |
| 2008 Q1 | 7.67 Million USD | 34.35% |
| 2008 FY | 35.42 Million USD | 12.23% |
| 2008 Q4 | 9.28 Million USD | -6.45% |
| 2008 Q3 | 9.92 Million USD | 16.08% |
| 2008 Q2 | 8.54 Million USD | 11.31% |
| 2007 Q1 | 8.25 Million USD | 56.39% |
| 2007 Q4 | 5.71 Million USD | -39.69% |
| 2007 FY | 31.56 Million USD | 38.33% |
| 2007 Q3 | 9.47 Million USD | 18.04% |
| 2007 Q2 | 8.02 Million USD | -2.76% |
| 2006 Q1 | 4.79 Million USD | 192.45% |
| 2006 Q3 | 5.71 Million USD | -14.87% |
| 2006 Q2 | 6.71 Million USD | 40.21% |
| 2006 FY | 22.81 Million USD | 111.9% |
| 2006 Q4 | 5.27 Million USD | -7.66% |
| 2005 Q4 | -5.18 Million USD | -270.65% |
| 2005 Q1 | 7.4 Million USD | -30.14% |
| 2005 Q2 | 5.51 Million USD | -25.5% |
| 2005 Q3 | 3.03 Million USD | -44.93% |
| 2005 FY | 10.76 Million USD | -63.17% |
| 2004 FY | 29.23 Million USD | 13.39% |
| 2004 Q1 | 7.85 Million USD | 22.04% |
| 2004 Q2 | 8.84 Million USD | 12.62% |
| 2004 Q3 | 2.6 Million USD | -70.5% |
| 2004 Q4 | 10.59 Million USD | 305.98% |
| 2003 Q4 | 6.43 Million USD | -0.51% |
| 2003 Q3 | 6.46 Million USD | -0.78% |
| 2003 Q1 | 6.36 Million USD | 8.55% |
| 2003 Q2 | 6.51 Million USD | 2.48% |
| 2003 FY | 25.78 Million USD | -21.88% |
| 2002 FY | 33 Million USD | 12.76% |
| 2002 Q4 | 5.86 Million USD | -27.15% |
| 2002 Q3 | 8.04 Million USD | -10.33% |
| 2002 Q2 | 8.97 Million USD | -11.45% |
| 2002 Q1 | 10.13 Million USD | 26.02% |
| 2001 Q2 | 8.56 Million USD | 40.98% |
| 2001 Q3 | 6.58 Million USD | -23.09% |
| 2001 Q4 | 8.03 Million USD | 22.02% |
| 2001 FY | 29.26 Million USD | 85.12% |
| 2001 Q1 | 6.07 Million USD | -1.62% |
| 2000 Q3 | 3.84 Million USD | 9.38% |
| 2000 Q2 | 3.51 Million USD | 55.23% |
| 2000 Q1 | 2.26 Million USD | 19.32% |
| 2000 FY | 15.81 Million USD | 155.02% |
| 2000 Q4 | 6.17 Million USD | 60.46% |
| 1999 Q3 | 2.1 Million USD | 90.91% |
| 1999 Q2 | 1.1 Million USD | 0.0% |
| 1999 FY | 6.2 Million USD | 0.0% |
| 1999 Q1 | 1.1 Million USD | -45.0% |
| 1999 Q4 | 1.9 Million USD | -9.52% |
| 1998 Q2 | 1.5 Million USD | 25.0% |
| 1998 Q1 | 1.2 Million USD | -20.0% |
| 1998 FY | 6.2 Million USD | 10.71% |
| 1998 Q3 | 1.5 Million USD | 0.0% |
| 1998 Q4 | 2 Million USD | 33.33% |
| 1997 Q4 | 1.5 Million USD | 7.14% |
| 1997 Q3 | 1.4 Million USD | 0.0% |
| 1997 Q1 | 1.3 Million USD | -31.58% |
| 1997 Q2 | 1.4 Million USD | 7.69% |
| 1997 FY | 5.6 Million USD | -5.08% |
| 1996 Q2 | 1.5 Million USD | 15.38% |
| 1996 FY | 5.9 Million USD | 0.0% |
| 1996 Q3 | 1.2 Million USD | -20.0% |
| 1996 Q1 | 1.3 Million USD | 0.0% |
| 1996 Q4 | 1.9 Million USD | 58.33% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | -183.079% |
| Alkermes plc | 996.24 Million USD | 21.794% |
| Agenus Inc. | 78.18 Million USD | -896.54% |
| Aptorum Group Limited | 10.56 Thousand USD | -7373787.942% |
| Ardelyx, Inc. | 169.93 Million USD | -358.479% |
| Dyadic International, Inc. | 9.15 Million USD | -8412.519% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -3401.213% |
| Lantern Pharma Inc. | 17.87 Million USD | -4258.115% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -11473.551% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -861.147% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -847.887% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -3912.279% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -2531.646% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -1366.55% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | -104.766% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -3105.404% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -1957.422% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -2432.011% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -819.69% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -4363.109% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -362.564% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -2281.553% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -387.602% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 56.717% |
| AlloVir, Inc. | 180.93 Million USD | -330.615% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | -74.795% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -2524.907% |
| Bicycle Therapeutics plc | 216.92 Million USD | -259.173% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -353.238% |
| ChromaDex Corporation | 56.37 Million USD | -1281.942% |
| Chimerix, Inc. | 93.38 Million USD | -734.279% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -5501.331% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -417.567% |
| CRISPR Therapeutics AG | 463.49 Million USD | -68.098% |
| Precision BioSciences, Inc. | 92.46 Million USD | -742.634% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -206.689% |
| Fortress Biotech, Inc. | 200.19 Million USD | -289.183% |
| Fortress Biotech, Inc. | 200.19 Million USD | -289.183% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -2279.298% |
| ImmuCell Corporation | 9.61 Million USD | -8001.234% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -393.698% |
| Immix Biopharma, Inc. | 16.14 Million USD | -4726.96% |
| Incyte Corporation | 1.19 Billion USD | 34.555% |
| Innoviva, Inc. | 132.15 Million USD | -489.558% |
| IO Biotech, Inc. | 91.44 Million USD | -752.034% |
| Jaguar Health, Inc. | 42.01 Million USD | -1754.397% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -360.266% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -823.977% |
| ContextLogic Inc. | 387 Million USD | -101.324% |
| MiMedx Group, Inc. | 229.72 Million USD | -239.153% |
| MEI Pharma, Inc. | 34.78 Million USD | -2139.83% |
| NextCure, Inc. | 67.63 Million USD | -1051.921% |
| Onconetix, Inc. | 34.9 Million USD | -2131.975% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -6012.702% |
| Opthea Limited | 191.96 Million USD | -305.863% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -28215.498% |
| Vaxcyte, Inc. | 468.04 Million USD | -66.465% |
| PDS Biotechnology Corporation | 43.04 Million USD | -1710.015% |
| Precigen, Inc. | 84.18 Million USD | -825.535% |
| Pharming Group N.V. | 225.49 Million USD | -245.524% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -364.243% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -973.678% |
| PureTech Health plc | 144.59 Million USD | -438.825% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -498.117% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -217.805% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -3105.404% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -240.705% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -2424.79% |
| Acelyrin, Inc. | 422.06 Million USD | -84.599% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -6042439.166% |
| Summit Therapeutics Inc. | 87.68 Million USD | -788.54% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -2002.107% |
| Senti Biosciences, Inc. | 94.7 Million USD | -722.686% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -530.6% |
| Elevation Oncology, Inc. | 45.44 Million USD | -1614.435% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -2543.88% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -19664.473% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -489.465% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -2185.83% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -9119.323% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -329.741% |
| Seer, Inc. | 110.49 Million USD | -605.154% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -1003.67% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -733.485% |
| ESSA Pharma Inc. | 32.13 Million USD | -2324.605% |
| GlycoMimetics, Inc. | 39.28 Million USD | -1883.249% |
| GT Biopharma, Inc. | 13.57 Million USD | -5638.988% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -254.422% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -287.403% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -200.328% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -1272.69% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -1340.69% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -7740.137% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | -93.062% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -4016.039% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -1436.948% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -200.057% |
| Aptose Biosciences Inc. | 52.35 Million USD | -1388.129% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -5306.695% |
| Soligenix, Inc. | 7.79 Million USD | -9894.867% |
| Century Therapeutics, Inc. | 56.07 Million USD | -1289.533% |
| Kura Oncology, Inc. | 165.8 Million USD | -369.907% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -580.417% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -9265.609% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -31295.582% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -623.435% |
| Autolus Therapeutics plc | 196.72 Million USD | -296.046% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -820.331% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -569.047% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -3919.631% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | -142.146% |
| GRI Bio, Inc. | 11.33 Million USD | -6776.655% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -10942.489% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -493.877% |
| IGM Biosciences, Inc. | 265.59 Million USD | -193.355% |
| INmune Bio, Inc. | 29.89 Million USD | -2506.118% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -351.525% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -1832.626% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -4775.821% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -4849.48% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -1154.67% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -624.619% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -182.606% |
| Coherus BioSciences, Inc. | 301.45 Million USD | -158.458% |
| Verastem, Inc. | 92.08 Million USD | -746.102% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -4243.191% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -319.505% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -541.746% |
| Histogen Inc. | 14.27 Million USD | -5359.116% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -4754.923% |
| Surrozen, Inc. | 18.55 Million USD | -4100.135% |
| Organovo Holdings, Inc. | 14.91 Million USD | -5123.768% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -15206.265% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -1205.654% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -2937.88% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -1557.501% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -10107.533% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -337.376% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -1508.169% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -218.005% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -4970.258% |
| Apollomics, Inc. | 54.14 Million USD | -1339.093% |
| Amarin Corporation plc | 272.35 Million USD | -186.068% |
| Mesoblast Limited | 5.9 Million USD | -13101.034% |
| Turnstone Biologics Corp. | 78.33 Million USD | -894.568% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -219.154% |
| Synaptogenix, Inc. | 8.31 Million USD | -9271.406% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -5241.595% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -207.886% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -2237.603% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -8722.379% |
| Exelixis, Inc. | 1.58 Billion USD | 50.899% |
| Better Therapeutics, Inc. | 38.26 Million USD | -1936.289% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -235.757% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 8.896% |
| NLS Pharmaceutics AG | 11.8 Million USD | -6498.804% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -9588.313% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -2497.689% |
| Gritstone bio, Inc. | 148.37 Million USD | -425.109% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -1031.446% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -4662.314% |
| Avid Bioservices, Inc. | 25.99 Million USD | -2897.096% |
| Insmed Incorporated | 949.26 Million USD | 17.923% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -4865.81% |
| MediWound Ltd. | 18.86 Million USD | -4029.346% |
| OmniAb, Inc. | 83.89 Million USD | -828.691% |
| Alector, Inc. | 248.8 Million USD | -213.151% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -232.522% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -1391.12% |
| Zai Lab Limited | 547.47 Million USD | -42.312% |
| Revance Therapeutics, Inc. | 398.65 Million USD | -95.439% |
| Aura Biosciences, Inc. | 84.99 Million USD | -816.715% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -215.259% |
| Immunic, Inc. | 99.22 Million USD | -685.226% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -389.979% |
| Veracyte, Inc. | 357.93 Million USD | -117.673% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 91.358% |
| FibroGen, Inc. | 398.11 Million USD | -95.704% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -5382.935% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -11211.426% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -10833.964% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 76.068% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -2911.344% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | -146.136% |
| TG Therapeutics, Inc. | 198.47 Million USD | -292.556% |
| Galecto, Inc. | 35.62 Million USD | -2086.895% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -1814.83% |
| Fortrea Holdings Inc. | 457.3 Million USD | -70.375% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -1335.434% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -2597.988% |
| XBiotech Inc. | 37.51 Million USD | -1977.113% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -1031.446% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -3673.185% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -448.444% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -686.399% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -603.715% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 18.693% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -2601.075% |
| Vaxxinity, Inc. | 56.05 Million USD | -1290.029% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | -80.923% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -3392.532% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -602.756% |
| NexImmune, Inc. | 28.16 Million USD | -2666.041% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -13986.645% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -4254.475% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 72.325% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -2960.313% |
| Scopus BioPharma Inc. | 11.71 Million USD | -6550.731% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -513.185% |
| Ainos, Inc. | 12.95 Million USD | -5915.172% |
| Pluri Inc. | 22.48 Million USD | -3365.859% |
| Prothena Corporation plc | 282.4 Million USD | -175.888% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -289.52% |
| Celularity Inc. | 215.05 Million USD | -262.286% |
| Rallybio Corporation | 78.93 Million USD | -887.084% |
| Cue Biopharma, Inc. | 19.54 Million USD | -3886.926% |
| MeiraGTx Holdings plc | 151.07 Million USD | -415.71% |
| Omeros Corporation | 94.75 Million USD | -722.287% |
| Humacyte, Inc. | 23.49 Million USD | -3215.849% |
| Immunocore Holdings plc | 308.04 Million USD | -152.93% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -22883.038% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -796.938% |
| Blueprint Medicines Corporation | 722.86 Million USD | -7.784% |
| CalciMedica, Inc. | 21.81 Million USD | -3471.183% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -943.564% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -385.315% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -354.844% |
| Sana Biotechnology, Inc. | 294.94 Million USD | -164.164% |
| Pulmatrix, Inc. | 22.03 Million USD | -3435.371% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -2153.435% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -776.741% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -41.257% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -973.9% |
| Cytokinetics, Incorporated | 173.61 Million USD | -348.774% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -2163.648% |
| Nutriband Inc. | 5.73 Million USD | -13487.736% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -1686.451% |
| Vor Biopharma Inc. | 126.03 Million USD | -518.177% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 34.482% |
| Evogene Ltd. | 27.79 Million USD | -2703.616% |
| ProKidney Corp. | 151.52 Million USD | -414.199% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -950.388% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -10028.711% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | -26.846% |
| CorMedix Inc. | 48.95 Million USD | -1491.422% |
| BioLineRx Ltd. | 50.8 Million USD | -1433.65% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -417.004% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -1946.451% |
| Atai Life Sciences N.V. | 125.78 Million USD | -519.41% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -854.35% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -857.05% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -208.501% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -2279.734% |
| MediciNova, Inc. | 10.9 Million USD | -7047.762% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -504.817% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -10632.453% |
| GeoVax Labs, Inc. | 6.02 Million USD | -12837.606% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -63.558% |
| Biomea Fusion, Inc. | 126.13 Million USD | -517.691% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 40.608% |
| Mereo BioPharma Group plc | 35.84 Million USD | -2073.777% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -307.729% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -238.818% |
| Absci Corporation | 73.66 Million USD | -957.645% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -2724.759% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -483.221% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -221.737% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -197.321% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -274.59% |
| Allakos Inc. | 196.05 Million USD | -297.399% |
| Imunon, Inc. | 20.31 Million USD | -3736.084% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -586.641% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -111.367% |
| BioAtla, Inc. | 129.68 Million USD | -500.773% |
| NLS Pharmaceutics AG | 11.8 Million USD | -6498.804% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -4817.787% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -817.503% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -1765.81% |
| XOMA Corporation | 46.46 Million USD | -1576.872% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -600.835% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -446.896% |
| aTyr Pharma, Inc. | 12.97 Million USD | -5902.966% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -651.645% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -350.7% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -205.822% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -1982.776% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -9372.859% |
| Akari Therapeutics, Plc | 16.8 Million USD | -4535.993% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -34162.765% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -160.3% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -11479.08% |
| UroGen Pharma Ltd. | 138.88 Million USD | -460.974% |
| Sutro Biopharma, Inc. | 243 Million USD | -220.616% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -10610.178% |
| Orgenesis Inc. | 45.75 Million USD | -1602.745% |
| Entera Bio Ltd. | 8.86 Million USD | -8693.736% |
| GH Research PLC | 41.22 Million USD | -1790.071% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -2930.671% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -838.106% |
| Xencor, Inc. | 306.97 Million USD | -153.806% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -15692.201% |
| Replimune Group, Inc. | 234.77 Million USD | -231.863% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -3702.485% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -306.226% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -11479.08% |
| Portage Biotech Inc. | 18.19 Million USD | -4181.142% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -10632.453% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -642.3% |
| OncoCyte Corporation | 25.63 Million USD | -2939.065% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -12681.746% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -6700.391% |
| Purple Biotech Ltd. | -22.46 Million USD | 3567.864% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -4627.7% |
| scPharmaceuticals Inc. | 65.17 Million USD | -1095.38% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -9117.43% |
| HilleVax, Inc. | 133.34 Million USD | -484.293% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -7475.352% |
| Tharimmune, Inc. | 9.45 Million USD | -8140.157% |
| Genprex, Inc. | 31.06 Million USD | -2408.406% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -315.476% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -2383.109% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -101746.405% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -14203.958% |
| OKYO Pharma Limited | 8243.57 USD | -9451205.684% |
| Savara Inc. | 15.74 Million USD | -4848.396% |
| Curis, Inc. | 58.35 Million USD | -1235.147% |
| Daré Bioscience, Inc. | 33.6 Million USD | -2218.176% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -15199.496% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -10342.635% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -2783.299% |
| BeiGene, Ltd. | 3.28 Billion USD | 76.294% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -3807.484% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | -56.211% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -407.071% |
| Erasca, Inc. | 141.52 Million USD | -450.521% |
| bluebird bio, Inc. | 240.23 Million USD | -224.322% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -17110.724% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 55.384% |
| DBV Technologies S.A. | 92.16 Million USD | -745.405% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -17110.724% |
| Moderna, Inc. | 6.39 Billion USD | 87.815% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -1728.546% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -5323.396% |
| Molecular Templates, Inc. | 63.09 Million USD | -1134.923% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -1068.086% |
| Travere Therapeutics, Inc. | 472 Million USD | -65.068% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -443.66% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -1154.993% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -1694.64% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -274.345% |
| MacroGenics, Inc. | 217.21 Million USD | -258.688% |
| RenovoRx, Inc. | 11.39 Million USD | -6736.829% |
| Adicet Bio, Inc. | 152.03 Million USD | -412.454% |
| Prime Medicine, Inc. | 186.63 Million USD | -317.45% |
| Aditxt, Inc. | 25.95 Million USD | -2902.32% |
| Adagene Inc. | 41.83 Million USD | -1762.538% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -10558.202% |
| Quantum-Si incorporated | 111.65 Million USD | -597.772% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -353.375% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -5244.611% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -2074.99% |
| SciSparc Ltd. | 9.01 Million USD | -8546.377% |
| Vericel Corporation | 142.04 Million USD | -448.525% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -8900.292% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -3274.502% |
| Generation Bio Co. | 144.46 Million USD | -439.31% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -838.366% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -801.139% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | -163.467% |
| Invivyd, Inc. | 205.75 Million USD | -278.666% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -979.734% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -8207.562% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -935.327% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -7473.88% |
| 2seventy bio, Inc. | 289.88 Million USD | -168.769% |
| ADMA Biologics, Inc. | 66.58 Million USD | -1070.103% |
| Clene Inc. | 41.07 Million USD | -1796.927% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -5983.166% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -1321.865% |
| GeoVax Labs, Inc. | 6.02 Million USD | -12837.606% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | -121.312% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -2021.106% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -2210.024% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -651.311% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -2290.761% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -357.561% |
| Vir Biotechnology, Inc. | 767.72 Million USD | -1.486% |
| Evaxion Biotech A/S | 22.27 Million USD | -3398.541% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -474.813% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -231.709% |
| Trevena, Inc. | 38.41 Million USD | -1928.285% |
| Surrozen, Inc. | 18.55 Million USD | -4100.135% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -874.576% |
| Cingulate Inc. | 22.75 Million USD | -3323.343% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 10499.426% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -1644.297% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -9362.358% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -659.692% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | -3.321% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -1155.155% |
| Clearmind Medicine Inc. | 8.74 Million USD | -8813.097% |
| Kronos Bio, Inc. | 128.11 Million USD | -508.131% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -826.735% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -26464.234% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -672.734% |
| Statera Biopharma, Inc. | 28.82 Million USD | -2602.526% |
| ImmunityBio, Inc. | 362.87 Million USD | -114.711% |
| Korro Bio, Inc. | 84.53 Million USD | -821.671% |
| Kineta, Inc. | 21.15 Million USD | -3582.761% |
| BioVie Inc. | 31.95 Million USD | -2338.56% |
| Codexis, Inc. | 66.51 Million USD | -1071.299% |
| Celularity Inc. | 215.05 Million USD | -262.286% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -243.801% |
| Celcuity Inc. | 66.23 Million USD | -1076.387% |
| Virax Biolabs Group Limited | 6.54 Million USD | -11800.374% |
| Cibus, Inc. | 320.3 Million USD | -143.245% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -1711.919% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -2202.107% |
| IN8bio, Inc. | 30.33 Million USD | -2468.234% |
| Kodiak Sciences Inc. | 277.32 Million USD | -180.947% |
| Annexon, Inc. | 143.72 Million USD | -442.102% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -510.643% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -3300.956% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -121638.281% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 0.059% |
| Eyenovia, Inc. | 25.4 Million USD | -2966.643% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -455.269% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -13908.001% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -884.577% |
| Arcellx, Inc. | 200.19 Million USD | -289.175% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -1597.44% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -260.021% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -7724.897% |
| Moolec Science SA | 52.75 Million USD | -1376.997% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -1174.371% |
| Geron Corporation | 70.44 Million USD | -1006.067% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -1574.098% |
| Royalty Pharma plc | 862.4 Million USD | 9.657% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -728.222% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -8252.661% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -3343.109% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -274.918% |
| Humacyte, Inc. | 23.49 Million USD | -3215.849% |
| Structure Therapeutics Inc. | 102.77 Million USD | -658.088% |
| 89bio, Inc. | 151.2 Million USD | -415.281% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -872.302% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -5258.494% |
| Genelux Corporation | 24.33 Million USD | -3101.664% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -2196.746% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -350.703% |
| Notable Labs, Ltd. | 14.77 Million USD | -5175.051% |
| Liquidia Corporation | 87.98 Million USD | -785.53% |
| Mustang Bio, Inc. | 48.5 Million USD | -1506.41% |
| Immunovant, Inc. | 282.7 Million USD | -175.593% |
| Quantum-Si incorporated | 111.65 Million USD | -597.772% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -3356.019% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -3563.54% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -663.758% |
| Acasti Pharma Inc. | 11.3 Million USD | -6794.301% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -3299.16% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -4775.821% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -1574.026% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -68570.786% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -4804.476% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -2572.171% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -1782.672% |
| PepGen Inc. | 84.76 Million USD | -819.148% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -2529.425% |
| United Therapeutics Corporation | 885.1 Million USD | 11.973% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -3302.738% |
| Solid Biosciences Inc. | 104.31 Million USD | -646.896% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -2280.786% |
| Immuneering Corporation | 58.41 Million USD | -1233.824% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -15206.265% |
| Silo Pharma, Inc. | 3.92 Million USD | -19766.232% |
| Belite Bio, Inc | 31.66 Million USD | -2360.291% |
| XOMA Corporation | 46.46 Million USD | -1576.872% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -1053.405% |
| Bionomics Limited | 17.89 Billion USD | 95.645% |
| Apogee Therapeutics, Inc. | 93 Million USD | -737.742% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 2283.646% |
| uniQure N.V. | 285.08 Million USD | -173.295% |
| Cassava Sciences, Inc. | 105.95 Million USD | -635.322% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -10558.202% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -301.183% |
| Forte Biosciences, Inc. | 32.47 Million USD | -2299.006% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -9277.157% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -2550.536% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -13908.001% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -5382.935% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -8665.047% |
| Altimmune, Inc. | 30.55 Million USD | -2449.827% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -82.187% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 2283.646% |
| Compugen Ltd. | 43.97 Million USD | -1671.906% |
| Peak Bio, Inc. | 1249.13 USD | -62373311.895% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -951.167% |
| Benitec Biopharma Inc. | 22.38 Million USD | -3381.034% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -220.378% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -2629.654% |
| Zura Bio Limited | 62.63 Million USD | -1143.854% |
| PolyPid Ltd. | 21.04 Million USD | -3602.186% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -4686.956% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -2629.654% |
| Instil Bio, Inc. | 85.78 Million USD | -808.23% |
| argenx SE | 1.53 Billion USD | 49.194% |
| Immunome, Inc. | 122.82 Million USD | -534.363% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -1507.338% |
| Verona Pharma plc | 67.15 Million USD | -1060.253% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -2909.948% |
| Shattuck Labs, Inc. | 93.61 Million USD | -732.274% |
| CervoMed Inc. | 14.95 Million USD | -5108.832% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -1001.969% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -9018.972% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -1427.696% |
| Moolec Science SA | 52.75 Million USD | -1376.997% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -4636.771% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -487.774% |
| AnaptysBio, Inc. | 181.56 Million USD | -329.109% |
| Design Therapeutics, Inc. | 78.19 Million USD | -896.451% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -795.124% |
| NeurAxis, Inc. | 8.82 Million USD | -8732.416% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -6090.902% |
| Lumos Pharma, Inc. | 38.66 Million USD | -1915.065% |
| Achilles Therapeutics plc | 75.25 Million USD | -935.313% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -2909.948% |
| 180 Life Sciences Corp. | 13.47 Million USD | -5680.931% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -2839.823% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -26464.234% |
| Nutriband Inc. | 5.73 Million USD | -13487.736% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -603.308% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -1299.969% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -1431.329% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -1078.724% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -1339.543% |
| Palisade Bio, Inc. | 13.32 Million USD | -5749.287% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -1615.794% |
| Beam Therapeutics Inc. | 554.19 Million USD | -40.587% |
| Neurogene Inc. | 55.58 Million USD | -1301.733% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -213.545% |
| AEON Biopharma, Inc. | 48.42 Million USD | -1508.798% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -705.63% |
| Sesen Bio, Inc. | 78.38 Million USD | -894.023% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -832.76% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -6089.969% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -72.758% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -786.477% |
| Athira Pharma, Inc. | 125.46 Million USD | -520.985% |
| Vaccinex, Inc. | 23.45 Million USD | -3221.786% |
| HCW Biologics Inc. | 21.02 Million USD | -3605.263% |
| XOMA Corporation | 46.46 Million USD | -1576.872% |
| Nektar Therapeutics | 190.9 Million USD | -308.126% |
| Arvinas, Inc. | 480 Million USD | -62.318% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -34162.765% |
| Merus N.V. | 200.49 Million USD | -288.603% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -653.834% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -2150.505% |
| Rezolute, Inc. | 70.38 Million USD | -1006.916% |
| Clene Inc. | 41.07 Million USD | -1796.927% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -4657.006% |
| BeyondSpring Inc. | 24.86 Million USD | -3033.42% |
| Synlogic, Inc. | 58.53 Million USD | -1231.109% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -4254.6% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -17244.724% |
| Peak Bio, Inc. | 1249.13 USD | -62373311.895% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -1188.96% |
| Krystal Biotech, Inc. | 160.42 Million USD | -385.66% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -187.892% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | -123.862% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -36025.225% |
| MannKind Corporation | 125.59 Million USD | -520.337% |
| Ikena Oncology, Inc. | 84.57 Million USD | -821.202% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -7976.345% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -769.549% |
| Gossamer Bio, Inc. | 183.75 Million USD | -323.993% |
| CohBar, Inc. | 12.38 Million USD | -6189.202% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -1436.009% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -2724.759% |
| Legend Biotech Corporation | 583.14 Million USD | -33.607% |
| Mural Oncology plc | 192.07 Million USD | -305.644% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -1060.327% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -4725.716% |
| Disc Medicine, Inc. | 91.12 Million USD | -755.007% |
| Champions Oncology, Inc. | 28.11 Million USD | -2671.7% |
| REGENXBIO Inc. | 321.15 Million USD | -142.599% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -14432.568% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -1297.383% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -1899.774% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -581.309% |
| Vaxart, Inc. | 90.72 Million USD | -758.767% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -9044.651% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -1720.637% |
| Cellectis S.A. | 97.32 Million USD | -700.581% |
| Longeveron Inc. | 21.25 Million USD | -3566.471% |
| Repare Therapeutics Inc. | 167.35 Million USD | -365.547% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 42.746% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -929.976% |
| Revolution Medicines, Inc. | 498.76 Million USD | -56.211% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -11612.643% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -1672.592% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -944.544% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -1018.87% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -6944.53% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 83.683% |
| Denali Therapeutics Inc. | 527.23 Million USD | -47.777% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -8900.292% |
| Veru Inc. | 101.34 Million USD | -668.761% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -3228.598% |
| Cingulate Inc. | 22.75 Million USD | -3323.343% |
| Passage Bio, Inc. | 108.38 Million USD | -618.823% |
| Context Therapeutics Inc. | 25.07 Million USD | -3007.474% |
| Exicure, Inc. | 14.07 Million USD | -5435.131% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -278.099% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -1699.323% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -8389.707% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -208.585% |
| Nuvalent, Inc. | 149.49 Million USD | -421.182% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -9558.293% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -651.688% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -3532.454% |
| OmniAb, Inc. | 83.89 Million USD | -828.691% |
| Anew Medical, Inc. | 1.3 Million USD | -59793.946% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -2277.991% |
| Lipocine Inc. | 15.08 Million USD | -5066.564% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -1037.193% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -923.118% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -1832.626% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -578.426% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -3380.723% |
| Sage Therapeutics, Inc. | 664.14 Million USD | -17.312% |
| Ocugen, Inc. | 71.56 Million USD | -988.665% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -730.04% |
| Q32 Bio Inc. | 92.68 Million USD | -740.661% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -3579.631% |
| Alumis Inc. Common Stock | 158.17 Million USD | -392.575% |
| Equillium, Inc. | 50.6 Million USD | -1439.59% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -1148.478% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -5502.977% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -4029.979% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -1559.443% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -618.313% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -6186.954% |
| Dominari Holdings Inc. | 23.83 Million USD | -3168.827% |
| Edesa Biotech, Inc. | 9.22 Million USD | -8347.853% |
| vTv Therapeutics Inc. | 11.9 Million USD | -6443.42% |
| Bio-Techne Corporation | 563.03 Million USD | -38.379% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -90.586% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -189.901% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -489.01% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -5306.46% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -375.958% |
| Nkarta, Inc. | 131.65 Million USD | -491.815% |
| BioCardia, Inc. | 12.12 Million USD | -6327.894% |
| Iterum Therapeutics plc | 47.46 Million USD | -1541.369% |